Adults with Down syndrome develop the neuropathological hallmarks of Alzheimer's
disease and are at very high risk of developing early-onset dementia, which is now the …

Tauvid has been approved by the US Food and Drug Administration (FDA) in 2020 for
positron emission tomography (PET) imaging of adult patients with cognitive impairments …

Limited comparative data exist on the molecular spectrum of amyloid-beta (Aβ) and tau
deposition in individuals with Down syndrome (DS) and sporadic Alzheimer's disease (sAD) …

Importance Novel plasma biomarkers, especially phosphorylated tau (p-tau), can detect
brain tau aggregates in Alzheimer disease. Objective To determine which plasma biomarker …

Abnormal accumulation of Tau protein is closely associated with neurodegeneration and
cognitive impairment and it is a biomarker of neurodegeneration in the dementia field …

Adults with Down syndrome (DS) are at risk for Alzheimer's disease. Despite sharing trisomy
21, however, there is variability in the age of disease onset. This variability may mean that …

Down syndrome (DS, trisomy 21) is characterized by intellectual impairment at birth and
Alzheimer's disease (AD) pathology in middle age. As individuals with DS age, their …

Women are disproportionately affected by Alzheimer's disease (AD), yet little is known about
sex-specific effects on the development of AD in the Down syndrome (DS) population. DS is …

INTRODUCTION Almost all individuals with Down syndrome (DS) will develop
neuropathological features of Alzheimer's disease (AD). Understanding AD biomarker …

This study investigates whether tau has (i) an independent effect from amyloid-β on changes
in cognitive and functional performance and (ii) a synergistic relationship with amyloid-β in …